Posted by Michael Wonder on 09 Mar 2020
Health economic assessment of Kadcyla in the treatment of HER2 positive, early breast cancer
6 March 2020 - TLV has developed a health economic knowledge base for the regions for the drug Kadcyla (trastuzumab emtansine).
The knowledge base evaluates Kadcyla in adjuvant treatment of patients with HER2-positive, early breast cancer.
TLV's health economic analysis shows that treatment with Kadcyla leads to a lower proportion of relapses compared to treatment with trastuzumab. This results in patients living longer and a smaller proportion of patients in need of later treatment than is needed with today's standard treatment.
